Cas no 56390-09-1 (Epirubicin hydrochloride)
Epirubicin hydrochloride Chemical and Physical Properties
Names and Identifiers
-
- Epirubicin HCl
- epirubicin hydrochloride
- l-erythro-dihydrosphingosine
- 4'-Epidoxorubicin hydrochloride
- 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.α.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride
- Epirubicin (hydrochloride)
- Epirubicin, Hydrochloride Salt (4'-Epidoxorubicin,Pharmorubicin?, Ellence?, Epirubicin Ebewe?, Pharmorubicin,Ridorubicin)
- (8S-cis)-10-[(3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride
- (7S,9S)-7-[(2R,4R,5R)-4-Amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-
- Adriamycin
- DOXORUBICIN
- 14-hydroxydaunomycin
- 4'-Epiadriamycin Pidorubicin hydrochloride 4'-epi-Adriamycin hydrochloride Epirubicin 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-.alpha.-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-
- 14-hydroxydaunorubicine
- Epirubicin
- (1S,3S)-3-glycoloyl-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1,2,3,4,6,11-hexahydrotetracen-1-yl 3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranoside
- (8S-cis)-10-((3-amino-2,3,6-trideoxy-alpha-L-lyxo-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione
- CCRIS 4477
- E-ADM
- (8S-cis)-10-((3-Amino-2,3,6-trideoxy-beta-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-5,12-naphthacenedione Hydrochloride
- Hydrochloride, Epirubicin
- 3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl-3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside Hydrochloride
- 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabinohexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S,10S)-
- Farmorubicina
- CPD000466308
- CHEMBL1200981
- Farmorubicin
- EPIRUBICIN HYDROCHLORIDE (EP MONOGRAPH)
- NS00087126
- EINECS 260-145-2
- (8S-cis)-10-((3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxynaphthacene-5,12-dione hydrochloride
- (2S,4S)-4-(3-Amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyloxy)-2,5,12-trihydroxy-2-hydroxyacetyl-7-methoxy-1,2,3,4-tetrahydrotetracene-6,11-dione monohydrochloride
- 5,12-NAPHTHACENEDIONE, 10-((3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSYL)OXY)-7,8,9,10-TETRAHYDRO-6,8,11-TRIHYDROXY-8-(HYDROXYACETYL)-1-METHOXY-, HYDROCHLORIDE, (8S-CIS)-
- 4'-epi-Adriamycin
- EPIRUBICIN HYDROCHLORIDE (USP MONOGRAPH)
- Q27253634
- 4'-epi-Doxorubicin
- EPIRUBICIN HYDROCHLORIDE [ORANGE BOOK]
- SCHEMBL3165
- (1S,3S)-3-GLYCOLOYL-1,2,3,4,6,11-HEXAHYDRO-3,5,12-TRIHYDROXY-10-METHOXY-6,11-DIOXO-1-NAPHTHACENYL 3-AMINO-2,3,6-TRIDEOXY-.ALPHA.-L-ARABINO-HEXOPYRANOSIDE HYDROCHLORIDE
- MLS000759412
- NSC759195
- EPIRUBICIN HYDROCHLORIDE [USP-RS]
- (8S,10S)-10-(((2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
- 4'-epi-DX
- 22966TX7J5
- EPIRUBICIN HCL [VANDF]
- Epirubicin hydrochloride, European Pharmacopoeia (EP) Reference Standard
- Ellence
- EPIRUBICIN HYDROCHLORIDE [USP MONOGRAPH]
- DTXSID50860297
- SR-01000763557-3
- Epirubicin hydrochloride [USAN:USP:JAN]
- EPIRUBICIN HYDROCHLORIDE [USAN]
- (7S,9S)-7-[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy-6,9,11-trihydroxy-9-(2-hydroxyacetyl)-4-methoxy-8,10-dihydro-7H-tetracene-5,12-dione;hydrochloride
- BCP9000651
- EX-A2654
- AS-75323
- IMI-28
- UNII-22966TX7J5
- EPIRUBICIN HYDROCHLORIDE [MART.]
- NC00200
- Epirubicin hydrochloride (USAN:USP:JAN)
- NSC 256942
- CS-1773
- Epirubicin HCl (4'-epidoxorubicin)?
- CCG-100950
- (8S,10S)-10-((2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yloxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dione hydrochloride
- Epirubicin hydrochlorid
- Pidorubicin
- Epirubicin hydrochloride, British Pharmacopoeia (BP) Reference Standard
- NSC-759195
- E0840
- SR-01000763557
- EPIRUBICIN HYDROCHLORIDE (USP-RS)
- (8S,10S)-10-{[(2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyloxan-2-yl]oxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione hydrochloride
- Pharmakon1600-01505708
- SMR000466308
- DTXCID001475450
- 5,12-Naphthacenedione, 10-[(3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy]-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-, hydrochloride (1:1), (8S,10S)-
- Pharmorubicin Pfs
- Epirubicin hydrochloride (JP18/USP)
- MLS001401404
- Epidoxorubicin hydrochloride
- (1S,3S)-3-Glycoloyl-1,2,3,4,6,11-hexahydro-3,5,12-trihydroxy-10-methoxy-6,11-dioxo-1-naphthacenyl 3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranoside hydrochloride
- EPIRUBICIN HYDROCHLORIDE [MI]
- 4'-epi-Adriamycin hydrochloride
- (8S,10S)-10-(((2R,4S,5R,6S)-4-amino-5-hydroxy-6-methyltetrahydro-2H-pyran-2-yl)oxy)-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-7,8,9,10-tetrahydrotetracene-5,12-dionehydrochloride
- MFCD00941448
- Ellence (TN)
- Epirubicin hydrochloride, United States Pharmacopeia (USP) Reference Standard
- Epirubicin Ebewe
- D02214
- Epirubitec
- 5,12-Naphthacenedione, 10-((3-amino-2,3,6-trideoxy-alpha-L-arabino-hexopyranosyl)oxy)-7,8,9,10-tetrahydro-6,8,11-trihydroxy-8-(hydroxyacetyl)-1-methoxy-, hydrochloride, (8S-cis)-
- EPIRUBICIN HYDROCHLORIDE [JAN]
- 56390-09-1 (HCl)
- EPIRUBICIN HYDROCHLORIDE (MART.)
- EPIRUBICIN HYDROCHLORIDE [EP MONOGRAPH]
- Q-101406
- Pharmorubicin
- s1223
- HY-13624A
- EPIRUBICIN HYDROCHLORIDE [WHO-DD]
- AKOS030526162
- D83113
- WP-697
- 56390-09-1
- Epirubicin hydrochloride, >=90% (HPLC)
- Epirubicin hydrochloride
-
- MDL： MFCD00941448
- Inchi： 1S/C27H29NO11.ClH/c1-10-22(31)13(28)6-17(38-10)39-15-8-27(36,16(30)9-29)7-12-19(15)26(35)21-20(24(12)33)23(32)11-4-3-5-14(37-2)18(11)25(21)34;/h3-5,10,13,15,17,22,29,31,33,35-36H,6-9,28H2,1-2H3;1H/t10?,13-,15+,17+,22+,27+;/m1./s1
- InChI Key： MWWSFMDVAYGXBV-DPZLWMTJSA-N
- SMILES： Cl[H].O([C@@]1([H])C([H])([H])[C@]([H])([C@]([H])(C([H])(C([H])([H])[H])O1)O[H])N([H])[H])[C@]1([H])C2C(=C3C(C4C(=C([H])C([H])=C([H])C=4C(C3=C(C=2C([H])([H])[C@@](C(C([H])([H])O[H])=O)(C1([H])[H])O[H])O[H])=O)OC([H])([H])[H])=O)O[H]
Computed Properties
- Exact Mass: 579.151
- Monoisotopic Mass: 579.151
- Isotope Atom Count: 0
- Hydrogen Bond Donor Count: 7
- Hydrogen Bond Acceptor Count: 12
- Heavy Atom Count: 40
- Rotatable Bond Count: 5
- Complexity: 977
- Covalently-Bonded Unit Count: 2
- Defined Atom Stereocenter Count: 6
- Undefined Atom Stereocenter Count : 0
- Defined Bond Stereocenter Count: 0
- Undefined Bond Stereocenter Count: 0
- Surface Charge: 0
- Tautomer Count: 81
- Topological Polar Surface Area: 206
- XLogP3: -1.899
Experimental Properties
- Color/Form: Orange red crystalline solid
- Density: 1.61g/cm3
- Melting Point: 185°C
- Boiling Point: 810.3°C at 760 mmHg
- Flash Point: 443.8℃
- Refractive Index: 1.709
- Solubility: Soluble in DMSO to 100mM, or in ethanol to 10mM
- PSA: 206.07000
- LogP: 1.50360
- Specific Rotation: 274° (c=0.01, in methanol)
- Solubility: Not determined
- Vapor Pressure: No data available
Epirubicin hydrochloride Security Information
-
Symbol:
- Signal Word：Warning
- Hazard Statement： H302
- Warning Statement： P264; P270; P301+P312; P330; P501
- WGK Germany：3
- Hazard Category Code： 22-63-62-46-40
- Safety Instruction： 36/37/38-45-46
- RTECS：QI9295750
-
Hazardous Material Identification：
- Storage Condition：4°C, protect from light
Epirubicin hydrochloride Customs Data
- Customs Data：
China Customs Code:
2932999099Overview:
2932999099. Other heterocyclic compounds containing only oxygen heteroatoms. VAT:17.0%. Tax refund rate:13.0%. Regulatory conditions:nothing. MFN tariff:6.5%. general tariff:20.0%
Declaration elements:
Product Name, component content, use to
Summary:
2932999099. other heterocyclic compounds with oxygen hetero-atom(s) only. VAT:17.0%. Tax rebate rate:13.0%. . MFN tariff:6.5%. General tariff:20.0%
Epirubicin hydrochloride Pricemore >>
| Related Categories | No. | Product Name | Cas No. | Purity | Specification | Price | update time | Inquiry |
|---|---|---|---|---|---|---|---|---|
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-QZ388-50mg |
Epirubicin hydrochloride |
56390-09-1 | 98+% | 50mg |
4106CNY | 2021-05-07 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-QZ388-10mg |
Epirubicin hydrochloride |
56390-09-1 | 98+% | 10mg |
1121CNY | 2021-05-07 | |
| SHANG HAI XIAN DING Biotechnology Co., Ltd. | B-QZ388-5mg |
Epirubicin hydrochloride |
56390-09-1 | 98+% | 5mg |
653CNY | 2021-05-07 | |
| MedChemExpress | HY-13624A-10mM*1mLinDMSO |
Epirubicin hydrochloride |
56390-09-1 | 99.15% | 10mM*1mLinDMSO |
￥657 | 2023-07-26 | |
| MedChemExpress | HY-13624A-5mg |
Epirubicin hydrochloride |
56390-09-1 | 99.15% | 5mg |
￥515 | 2025-04-16 | |
| MedChemExpress | HY-13624A-10mg |
Epirubicin hydrochloride |
56390-09-1 | 99.15% | 10mg |
￥871 | 2025-04-16 | |
| MedChemExpress | HY-13624A-50mg |
Epirubicin hydrochloride |
56390-09-1 | 99.15% | 50mg |
￥3069 | 2025-04-16 | |
| MedChemExpress | HY-13624A-100mg |
Epirubicin hydrochloride |
56390-09-1 | 99.15% | 100mg |
￥4725 | 2025-04-16 | |
| TI XI AI ( SHANG HAI ) HUA CHENG GONG YE FA ZHAN Co., Ltd. | E0840-50MG |
Epirubicin Hydrochloride |
56390-09-1 | >95.0%(HPLC) | 50mg |
￥860.00 | 2024-04-16 | |
| HE FEI BO MEI SHENG WU KE JI YOU XIAN ZE REN GONG SI | BE4238-100mg |
Epirubicin hydrochloride |
56390-09-1 | ≥98% | 100mg |
￥1750.00 元 | 2023-09-15 |
Epirubicin hydrochloride Suppliers
Audited Supplier
Audited Supplier
Epirubicin hydrochloride Related Literature
-
Jing Yu,Yu-Qi Lyu,Jiapeng Liu,Mohammed B. Effat,Junxiong Wu J. Mater. Chem. A, 2019,7, 17995-18002
-
Qiyuan Wu,Shangmin Xiong,Peichuan Shen,Shen Zhao,Alexander Orlov Catal. Sci. Technol., 2015,5, 2059-2064
-
Eric Besson,Stéphane Gastaldi,Emily Bloch,Selma Aslan,Hakim Karoui,Olivier Ouari,Micael Hardy Analyst, 2019,144, 4194-4203
-
Zhixia Liu,Tingjian Chen,Floyd E. Romesberg Chem. Sci., 2017,8, 8179-8182
-
Kay S. McMillan,Anthony G. McCluskey,Annette Sorensen,Marie Boyd,Michele Zagnoni Analyst, 2016,141, 100-110
Additional information on Epirubicin hydrochloride
Epirubicin Hydrochloride: A Comprehensive Overview of its Chemistry, Applications, and Recent Research Developments
Epirubicin hydrochloride, a derivative of the naturally occurring anthracycline antibiotic epirubicin, is a critical compound in modern chemotherapy. With the CAS number 56390-09-1, this compound has garnered significant attention due to its potent antitumor properties. The chemical structure of epirubicin hydrochloride features an anthracycline core, which is a well-known pharmacophore in the development of anticancer agents. This introduction aims to provide a detailed exploration of the compound's chemical properties, therapeutic applications, and the latest advancements in research that highlight its importance in oncology.
The molecular formula of epirubicin hydrochloride is C??H??NO??·HCl, reflecting its complex structure that includes multiple functional groups essential for its biological activity. The anthracycline ring system is responsible for the compound's ability to intercalate into DNA, leading to the inhibition of topoisomerase II and subsequent DNA damage. This mechanism is crucial for its effectiveness in treating various types of cancer. The hydrochloride salt form enhances the solubility and stability of epirubicin hydrochloride, making it more suitable for intravenous administration in clinical settings.
In clinical oncology, epirubicin hydrochloride is primarily used as an effective chemotherapeutic agent for the treatment of several solid tumors and hematological malignancies. Its mechanism of action involves the induction of apoptosis in cancer cells by generating reactive oxygen species (ROS) and causing DNA strand breaks. This makes it particularly useful in treating aggressive forms of cancer such as breast cancer, lung cancer, and certain leukemias. The compound's efficacy has been well-documented in numerous clinical trials, where it has demonstrated significant tumor response rates in patients.
Recent research has focused on optimizing the therapeutic index of epirubicin hydrochloride by exploring novel formulations and combination therapies. One promising area of investigation is the development of liposomal formulations that can target tumors more selectively, thereby reducing systemic toxicity. These liposomal carriers have shown potential in improving drug delivery efficiency and minimizing side effects associated with conventional chemotherapy regimens.
Another significant advancement in the field involves the use of epirubicin hydrochloride in combination with other chemotherapeutic agents or targeted therapies. Studies have indicated that combining epirubicin hydrochloride with agents that inhibit specific signaling pathways can enhance antitumor activity while maintaining a manageable toxicity profile. For instance, combinations with tyrosine kinase inhibitors have shown synergistic effects in preclinical models, leading to improved outcomes for patients with advanced-stage cancers.
The pharmacokinetics of epirubicin hydrochloride have also been extensively studied to optimize dosing regimens and minimize adverse effects. Research has demonstrated that dose-dense chemotherapy regimens can improve patient outcomes by increasing exposure to the drug while maintaining acceptable levels of toxicity. Additionally, efforts have been made to develop biomarkers that can predict response to treatment and identify patients who may benefit most from epirubicin hydrochloride-based therapies.
From a chemical perspective, the synthesis and characterization of epirubicin hydrochloride continue to be areas of active research. Advances in synthetic methodologies have enabled the production of more pure and stable forms of the compound, which is essential for ensuring consistent therapeutic efficacy. Furthermore, structural modifications aimed at enhancing bioavailability and reducing metabolic clearance are being explored to develop next-generation derivatives with improved pharmacological properties.
The role of epirubicin hydrochloride in personalized medicine is another emerging trend in oncology research. By integrating genomic data with traditional clinical parameters, clinicians can better tailor treatment strategies to individual patients. This approach holds promise for optimizing the use of epirubicin hydrochloride by identifying patients who are most likely to respond positively to therapy while sparing those who may experience significant side effects.
In conclusion, epirubicin hydrochloride remains a cornerstone in modern cancer therapy due to its potent antitumor activity and well-established clinical efficacy. Ongoing research continues to uncover new applications and improve upon existing formulations, ensuring that this compound will remain a vital tool in the fight against cancer for years to come. The latest advancements in drug delivery systems, combination therapies, and personalized medicine highlight the dynamic nature of oncology research and underscore the importance of compounds like epirubicin hydrochloride in improving patient outcomes.
56390-09-1 (Epirubicin hydrochloride) Related Products
- 25316-40-9(Doxorubicin Hydrochloride)
- 58957-92-9(Idarubicin)
- 23214-92-8((8S,10S)-10-{(2R,4S,5S,6S)-4-amino-5-hydroxy-6-methyloxan-2-yloxy}-6,8,11-trihydroxy-8-(2-hydroxyacetyl)-1-methoxy-5,7,8,9,10,12-hexahydrotetracene-5,12-dione)
- 56420-45-2(Epirubicin)
- 72496-41-4(Pirarubicin)
- 20830-81-3(Daunomycin)
- 50935-04-1(Carminomicin I)
- 108852-90-0(Nemorubicin)
- 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
- 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
